Viral therapy for glioblastoma.
Malignant gliomas remain amongst the most difficult cancer to treat. Viral-based gene therapies have been employed for the last decade in preclinical and clinical modes as a novel treatment modality. In this review, such therapies are summarized. The overwhelming majority of clinical studies point one to conclude that methodologies that will increase tumor infection/transduction will lead to enhanced therapeutic results.
Chiocca
E Antonio
EA
Molecular Neuro-oncology Laboratory, Neurosurgery Service, Massachusetts General Hospital-East, Charlestown, Massachusetts 02129, USA. Chiocca@helix.mgh.harvard.edu
Aghi
Manish
M
Fulci
Giulia
G
D000256:Adenoviridae; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000235:genetics* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D000229:Dependovirus; D005437:Flucytosine / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005909:Glioblastoma / Q000235:genetics* / Q000628:therapy*; D006564:Herpesviridae; D006801:Humans; D012089:Mammalian orthoreovirus 3; D012190:Retroviridae; D019076:Transgenes / Q000187:drug effects*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D003520:Cyclophosphamide; D005437:Flucytosine; D015774:Ganciclovir